Orforglipron

Mechanism

Orforglipron is a small-molecule, non-peptide agonist of the GLP-1 (glucagon-like peptide-1) receptor. Unlike injectable GLP-1 agonists (semaglutide, tirzepatide) which are peptide-based, orforglipron's small-molecule structure allows oral absorption. It mimics the action of endogenous GLP-1, which is released from intestinal L-cells in response to food intake. GLP-1 receptor activation stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon secretion, slows gastric emptying, and reduces appetite through central nervous system effects on the hypothalamus. The result is improved glycaemic control and significant weight loss.

Evidence base

FDA Approval (2026)

Orforglipron received FDA approval in 2026 for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity. The approval was based on the ATTAIN Phase 3 programme, which included the ATTAIN-1 and ATTAIN-2 randomised controlled trials. These trials demonstrated substantial, clinically meaningful weight loss with orforglipron compared to placebo, with a safety profile consistent with the GLP-1 agonist class (primarily gastrointestinal adverse events).

Sources:

• FDA Drugs@FDA database, Application No. 218178 (orforglipron/Foundayo)
• DailyMed FDA label, setid 8ac446c5-feba-474f-a103-23facb9b5c62
• Eli Lilly press release: "US FDA Approves Foundayo™ (Orforglipron) Tablets, First and Only Oral GLP-1 for Obesity"

Pre-Approval Clinical Evidence

Prior to approval, Phase 2 data published in the New England Journal of Medicine (2023) demonstrated that orforglipron achieved weight loss of up to 14.7% at 36 weeks, competitive with injectable GLP-1 agonists. This was the first demonstration that an oral small-molecule GLP-1 agonist could achieve weight loss approaching that of injectable agents.

Evidence Quality Assessment

• Evidence grade: Strong — Upgraded from moderate following FDA approval based on Phase 3 RCT data.
• Large-scale, randomised, placebo-controlled Phase 3 trials (ATTAIN programme).
• Limitations: Long-term cardiovascular outcomes trials and head-to-head comparisons with tirzepatide are not yet published. Real-world effectiveness data is not yet available.
• UK-specific data: No UK-based clinical trial data has been published separately; ATTAIN trial sites were primarily US-based.

Protocols

FDA-Approved Dosing (Foundayo)

Research use only — this describes the approved pharmaceutical regimen for educational purposes. Not medical advice.

Orforglipron is administered as an oral tablet once daily with a gradual dose-escalation schedule:

• The titration schedule begins at a low dose and increases stepwise over several weeks to the target maintenance dose.
• Unlike oral semaglutide (Rybelsus), orforglipron does not require fasting before administration or a waiting period before eating.
• The full titration schedule and maintenance dose should be referenced from the FDA prescribing information.

Research Context

In pre-approval Phase 2 studies, orforglipron was studied at doses ranging from 12 mg to 45 mg once daily, with the 45 mg dose showing the greatest weight loss. The Phase 3 ATTAIN programme used a titration schedule to reach the approved maintenance dose. Researchers should consult the FDA label for the exact approved dosing regimen.

Cycle Length

Orforglipron is intended for chronic, long-term use. No cycling protocol is applicable to the approved pharmaceutical product. For research contexts, study designs have used continuous daily administration for 36–72 weeks.

UK legal status

Current status: UK grey area (not yet licensed)

Orforglipron is not yet licensed by the MHRA or the EMA. It received FDA approval in the United States in 2026 under the brand name Foundayo.

Key points:

• Orforglipron is not a controlled substance under the Misuse of Drugs Act 1971.
• It is not listed on the MHRA's register of licensed medicines.
• As an unlicensed GLP-1 receptor agonist, it falls into a UK grey area: it may be imported or possessed for legitimate research purposes, but cannot be marketed, advertised, or sold as a medicine without MHRA licensing.
• Eli Lilly is expected to seek EMA approval; MHRA licensing would likely follow or proceed in parallel. Researchers should monitor MHRA and EMA regulatory channels for updates.
• Once licensed in the UK, orforglipron would almost certainly be classified as a Prescription-Only Medicine (POM), consistent with other GLP-1 agonists (semaglutide, tirzepatide, liraglutide).

Comparison with other GLP-1 agonists in the UK

• Semaglutide (Wegovy, Ozempic): MHRA-licensed, POM
• Tirzepatide (Mounjaro): MHRA-licensed, POM
• Liraglutide (Saxenda, Victoza): MHRA-licensed, POM
• Orforglipron (Foundayo): FDA-approved only; not yet MHRA-licensed

Research use

For research purposes, orforglipron may be studied in UK laboratories. However, it should not be represented as a licensed medicine, and any supply for human consumption would constitute an offence under UK medicines regulations.

Vendor notes

As an oral pharmaceutical tablet, orforglipron (Foundayo) is not available through UK research peptide vendors, who typically sell lyophilised peptide powders for research use. The pharmaceutical product is not yet available in UK pharmacies. Researchers seeking pharmaceutical-grade material should await MHRA licensing. Research-grade orforglipron may be available from some international suppliers; verify purity and authenticity independently.